COMMUNIQUÉS West-GlobeNewswire
-
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
30/01/2026 -
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
30/01/2026 -
IO Biotech Provides Corporate Update
30/01/2026 -
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
30/01/2026 -
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
30/01/2026 -
Communiqué de presse : Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
30/01/2026 -
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
30/01/2026 -
Immunocore announces R&D leadership evolution
30/01/2026 -
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
30/01/2026 -
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations
30/01/2026 -
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01/2026 -
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
30/01/2026 -
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
30/01/2026 -
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
30/01/2026 -
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
30/01/2026 -
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
30/01/2026 -
Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
30/01/2026 -
PhenQ 2026: OTC appetite suppressant search analysis for phentermine alternatives
30/01/2026 -
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
30/01/2026
Pages